Please login to the form below

NHSE

This page shows the latest NHSE news and features for those working in and with pharma, biotech and healthcare.

National Institute for Health and Care Excellence (NICE) and NHS England and Improvement (NHSE&I).

Vertex scores FDA approval for CF triple therapy Trikafta

Trikafta is priced similarly to Kalydeco – Vertex and NHS England (NHSE) reached a pricing deal for this first CF drug in 2013. ... However, since then NHSE’s specialised commissioning head John Stewart has said that it overpaid for Kalydeco.
NHS England wants money-back guarantee on Orkambi

Meanwhile in his letter, Vertex's head of northern Europe Simon Lem has responded to this claim, saying it is “disappointed with NHSE’s characterisation of our participation in the negotiations”.
Gilead gets 'gold' in England's hepatitis C eradication drive

However, it ran into trouble when AbbVie mounted a legal action against NHSE, accusing it of of not treating all bidders fairly. ... The resulting High Court case ended triumphantly for NHSE however, which saw the judge ruling in its favour.
Leader named for NHS digital transformation unit, but scepticism persists

NHSE has confirmed such projects will be rolled out more widely across the health service to ensure “all systems can talk to each other”. .
Optimism on Orkambi in England as talks to resume

Constructive meeting with Vertex CEO with NHSE &NICE to find ways of breaking the impasse on Orkambi so that we can get this to those who desperately need it. ... Vertex, NHSE and NICE will meet again next week.”. A Vertex spokesperson commented: “We

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

The UK’s new medicines pricing deal – opportunities and risks for pharma

This is further evidence of the influence of NHSE. New incentives to greater cost-effectiveness. ... A single point of contact with NHSE and NICE offering greater consistency and clarity of advice.
Vertex: a vision of treating all CF patients worldwide draws closer

After its grilling of Jeff Leiden and his NHSE and NICE counterparts, the chair of the health select committee, Dr Sarah Wollaston MP wrote to the health secretary suggesting the government
The Orkambi row explained

April 2018: Vertex meets with NHSE to discuss access to Orkambi and future treatments. ... March 2019: Vertex, NHSE and NICE meet with Matt Hancock to recommence discussions on cystic fibrosis medicines.
#OrkambiNow?

Fast forward to July 2018, and the row had escalated to the point where Vertex branded NHSE’s behaviour as ‘outrageous’ and ‘unconscionable’.
NHS regional footprints

What to expect from 2019. Towards the end of 2018, a map was published by NHS England (NHSE) and NHS Improvement (NHSI), which divided the country into 42 ‘regional footprints’ responsible ... The widening role of CCGs was underlined by the recent

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Will the NHS be safe in Liz Truss’s Hands?

The higher than planned 5% pay increase this year blew a roughly £2 billion hole in NHS England’s (NHSE) finances – and NHSE leaders have highlighted real-terms budget cuts ... When former Health Secretary Sajid Javid gave a speech in the spring,
What next for health? The weeks that have seen a whirlwind in Whitehall.

In her latest blog, Ursula Ritz considers the implications of the change of senior leadership at DHSC and NHSE for existing priorities, including for those of us committed to ensuring the ... NHSE Chief Executive, Amanda Pritchard, will certainly have
Understanding the role of provider collaboratives

NHSE/I is expected to set out guidance on how to do this soon.
How does the government plan to reshape the NHS?

Integrated care. The white paper confirms that NHS England (NHSE) is backing legislation to abolish Clinical Commissioning Groups (CCGs). ... Also of particular note in the white paper is the inclusion of NHSE’s recommendation for a reserve power to
Integrated NHS finances: what do they mean for High Cost Drugs?

NHS England (NHSE) Specialised Commissioning will continue to retain the budget for cancer and certain rare diseases. ... So, clinical service directors who previously passed the bill for High Cost Drugs on to CCGs, or were reimbursed by NHSE, will now

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...: Highly competitive salary

Exciting Medical Writer Career Opportunity for Postdoc, Medcomms: Highly competitive salary

Add my company

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Virtual Steering Committee & Peer Influence Program: In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges: The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement: How does Pharma-HCP engagement need to evolve in today's digital landscape?...

Email:
Password: